Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Number of holders
-
52
-
Total 13F shares, excl. options
-
37M
-
Shares change
-
+9.49M
-
Total reported value, excl. options
-
$46.6M
-
Value change
-
+$10.7M
-
Put/Call ratio
-
1.04
-
Number of buys
-
32
-
Number of sells
-
-23
-
Price
-
$1.26
Significant Holders of GLYCOMIMETICS INC - Common Stock, par value $0.001 per share (GLYC) as of Q1 2023
77 filings reported holding GLYC - GLYCOMIMETICS INC - Common Stock, par value $0.001 per share as of Q1 2023.
GLYCOMIMETICS INC - Common Stock, par value $0.001 per share (GLYC) has 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37M shares
.
Largest 10 shareholders include BVF INC/IL (9.54M shares), Artal Group S.A. (8.59M shares), NEA Management Company, LLC (4.76M shares), Octagon Capital Advisors LP (3M shares), VANGUARD GROUP INC (2.46M shares), AXA S.A. (1.61M shares), ACADIAN ASSET MANAGEMENT LLC (1.4M shares), GOLDMAN SACHS GROUP INC (902K shares), BlackRock Inc. (649K shares), and TWO SIGMA ADVISERS, LP (595K shares).
This table shows the top 52 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.